Calcium and phosphate handling in peritoneal dialysis

Contributions to Nephrology

Volumn 150, Issue , 2006, Pages 214-225

  Cozzolino, Mario ^a,b   Gallieni, Maurizio ^a   Chiarelli, Giusy ^a   Brancaccio, Diego ^a  

^a SAN PAOLO HOSPITAL   (Italy)

^b Azienda Ospedale San Paolo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PHOSPHATE;

ACIDOSIS; BONE; CALCINOSIS; HUMAN; METABOLISM; PERITONEAL DIALYSIS; RENAL OSTEODYSTROPHY; REVIEW; VASCULAR DISEASE;

ACIDOSIS; BONE AND BONES; CALCINOSIS; CALCIUM; HUMANS; PERITONEAL DIALYSIS; PHOSPHATES; RENAL OSTEODYSTROPHY; VASCULAR DISEASES;

EID: 33745263744     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000093597     Document Type: Review

References (53)

1. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT, for the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group: The kidney disease outcomes quality initiative (K/DOQI) guideline for bone metabolism and disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005;46:925-932.
2. Cozzolino M, Dusso A, Slatopolsky E: Role of calcium x phosphate product and bone associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 2001;12:2511-2516.
3. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-2138.
4. London GM: Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 2003;14:S305-S309.
5. Christian RC, Fitzpatrick LA: Vascular calcification. Curr Opin Nephrol Hypertens 1999;8:443-448.
6. Ansari A, Kaupke CJ, Vaziri ND, et al: Cardiac pathology in patients with end-stage renal disease maintained on hemodialysis. Int J Artif Organs 1993;16:31-36.
7. Schwartz U, Buzzello M, Ritz E, et al: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000;15:218-223.
8. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E: Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005;68:429-436.
9. Braun J, Oldendorf M, Moshage W, et al: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996;27:394-401.
10. Goodman WG, Goldin J, Kuizon BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483.
11. London GM, Pannier B, Marchais SJ, Guerin AP: Calcification of the aortic valve in the dialyzed patient. J Am Soc Nephrol 2000;11:778-783.
12. Jono S, McKee MD, Murry CE, et al: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87:E10-E17.
13. Chertow GM, Burke SK, Raggi P, et al: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-252.
14. Chertow GM, Burke SK, Dillon MA, Slatopolsky E: Long-term effects of sevelamer hydrochloride on the calcium X phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant 1999;14:2907-2914.
15. Hergesell O, Ritz E: Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant 1999;14:863-867.
16. Hutchinson AJ: Calcitriol, lanthanum carbonate and other new phosphate binders in the management of renal osteodystrophy. Peri Dial Int 1999;19(suppl 2):S408-S412.
17. Kuro-o M, Matsumura Y, Aizawa H, et al: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51.
18. Giachelli CM: Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003;14(suppl):S300-S304.
19. Ducy P, Zhang R, Geoffroy V, et al: Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997;89:747-754.
20. Wada T, McKee MD, Steitz S, Giachelli CM: Calcification of vascular smooth muscle cell cultures. Inhibition by osteopontin. Circ Res 1999;84:166-178.
21. Jono S, Peinado C, Giachelli CM: Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 2000;275:20197-20203.
22. Giachelli CM, Speer MY, Li X, et al: Regulation of vascular calcification. Roles of phosphate and osteopontin. Circ Res 2005;96:717-722.
23. Speer MY, Chien Y-C, Quan M, et al: Smooth muscle cells deficient in osteopontin have enhanced susceptibility to calcification in vitro. Cardiovasc Res 2005;66:324-333.
24. Luo G, Hofmann C, Bronckers AL, et al: BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. Genes Dev 1995;9:2808-2820.
25. Wang S-N, Lapage J, Hirschberg R: Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 2001;12:2392-2399.
26. Wang S, Chen Q, Simon TC, et al: Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 2003;63:2037-2049.
27. Dorai H, Vukicevic S, Sampath TK: Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol 2000;184:37-45.
28. Baskies AM, Chretien PB, Weiss JF, et al: Serum glycoproteins in cancer patients: first report of correlations with in vitro and in vivo parameters of cellular immunity. Cancer 1980;45:3050-3060.
29. Heiss A, DuChesne A, Denecke B, et al: Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 2003;278:13333-13341.
30. Demetriou M, Binker C, Sukhu B, et al: Fetuin/alpha2-HS glycoprotein is a transforming growth factor beta type II receptor mimic and cytokine antagonist. J Biol Chem 1996;271:12755-12761.
31. Schafer C, Heiss A, Schwarz A, et al: The serum protein alpha 2-Heremans -Schmid glycoprotein/ fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003;112:357-366.
32. Ketteier M, Bongartz P, Westenfeld R, et al: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003;361:827-833.
33. Luo G, Ducy P, McKee MD, et al: Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386:78-81.
34. Shearer MJ: Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification. Curr Opin Clin Nutr Metab Care 2000;3:433-438.
35. Zebboudj AF, Shin V, Bostrom K: Matrix GLA protein and BMP-2 regulate osteoinduction in calcifying vascular cells. J Cell Biochem 2003;90:756-765.
36. Kajbaf S, Veinot JP, Ha A, Zimmerman D: Comparison of surgically removed cardiac valves of patients with ESRD with those of the general population. Am J Kidney Dis 2005;46:86-93.
37. Carmen Sanchez M, Auxiliadora Bajo M, Selgas R, Mate A, Millan I, Eugenia Martinez M, et al: Parathormone secretion in peritoneal dialysis patients with adynamic bone disease. Am J Kidney Dis 2000;36:953-961.
38. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, et al: The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int 1993;43:436-442.
39. Moe SM: Management of renal osteodystrophy in peritoneal dialysis patients. Perit Dial Int 2004;24:209-216.
40. Kurz P, Tsobanelis T, Roth P, Werner E, Ewald U, Grutzmacher P, et al: Differences in calcium kinetic pattern between CAPD and HD patients. Clin Nephrol 1995;44:255-261.
41. Schmitt CP, Schaefer F, Huber D, Zahn I, Veldhuis JD, Ritz E, et al: 1,25(OH)2-vitamin D3 reduces spontaneous and hypocalcemia-stimulated pulsatile component of parathyroid hormone secretion. J Am Soc Nephrol 1998;9:54-62.
42. Ishizuya T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S, et al: Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest 1997;99:2961-2970.
43. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998;102:1627-1633.
44. Montenegro J, Saracho R, Gonzalez O, Moina I, Martinez I: Reversibility of parathyroid gland suppression in CAPD patients with low i-PTH levels. Clin Nephrol 1997;48:359-363.
45. Moe SM, Peterson JM, Murphy CL, Johnson EA, Deeg M: Sevelamer HCl improves parathyroid hormone (PTH) and bone function in peritoneal dialysis (PD) patients with probable low turnover bone disease. Am J Kidney Dis 2001;37:A25.
46. Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, et al: Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003;14:159-168.
47. Sanchez C, Lopez-Barea F, Sanchez-Cabezudo J, Bajo A, Mate A, Martinez E, Selgas R, for the Collaborators of the Multicentre Study Group: Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Nephrol Dial Transplant 2004;19:1587-1593.
48. Bender FH, Bernardini J, Piraino B: Calcium mass transfer with dialysate containing 1.25 and 1.75 mmol/L calcium in peritoneal dialysis patients. Am J Kidney Dis 1992;20:367-371.
49. Gallieni M, Cicchetti T, Salvadori M, Sorba G, Stalteri A, Tarchini R, Brancaccio D, CaCSE Study Investigators: Comparison of sevelamer HCl and calcium carbonate in the treatment of hyperphosphatemia in dialysis patients: a randomized clinical trial - calcium carbonate sevelamer evaluation (CaCSE) study [abstract]. J Am Soc Nephrol 2005;16:746A.
50. Gallieni M, Borgatti P, Bottalico D, et al: Mineral metabolism in 490 peritoneal dialysis patients: The ROCK-PD (Renal Osteodystrophy and Calcifications: Key Factors in Peritoneal Dialysis) Multicenter Study [abstract]. J Am Soc Nephrol 2005;16:456A.
51. Krieger NS, Frick KK, Bushinsky DA: Mechanism of acid-induced bone resorption. Curr Opin Nephrol Hypertens 2004;13:423-436.
52. Feriani M: Use of different buffers in peritoneal dialysis. Semin Dial 2000;13:256-260.
53. Weinreich T: Prevention of renal osteodystrophy in peritoneal dialysis. Kidney Int 1998;54:2226-2233.